证券代码：838810 证券简称：春光药装 公告编号：2024-014 辽宁春光制药装备股份有限公司 第三届监事会第十四次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 本次会议的召集、召开符合《公司法》《公司章程》《监事会议事规则》的相 关规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 3.回避表决情况 本议案不涉及关联交易，无需回避表决。 本议案尚需提交股东大会审议。 （二）审议通过《关于 2023 年年度报告及摘要的议案》 1.议案内容： 二、议案审议情况 （一）审议通过《关于 2023 年度监事会工作报告的议案》 1.议案内容： 公司监事会对 2023 年度工作运营情况、监事会工作情况进行了总结，形成 了 2023 年度监事会工作报告。 1.会议召开时间：2024 年 4 月 23 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出监事会会议通知的时间和方式：2024 年 4 月 10 日 ...

Financial Performance - Revenue for Q1 2024 was CNY 10,747,829.83, a significant decrease of 78.94% from CNY 51,045,814.36 in Q1 2023[12] - Net profit attributable to shareholders was a loss of CNY 3,342,147.31, down 143.49% from a profit of CNY 7,684,095.67 in the same period last year[12] - Operating profit for the same period was -4.04 million yuan, down 145.53% year-on-year, attributed to changes in market demand leading to decreased product revenue[15] - The net profit for the first quarter of 2024 was -3.50 million yuan, a decrease of 145.57% year-on-year, primarily due to a decline in revenue and gross margin[15] - The company's total comprehensive income for Q1 2024 was -¥4,077,480.89, compared to ¥7,982,611.80 in Q1 2023, highlighting a drastic shift in overall financial performance[52] Cash Flow - Operating cash flow for the quarter was a negative CNY 11,430,013.86, representing a decline of 305.55% compared to a negative CNY 2,818,387.26 in Q1 2023[12] - The net cash flow from operating activities was -12,258,376.66, compared to -2,433,742.72 in the previous year, indicating a significant decline[56] - Cash inflow from financing activities amounted to 12,589,419.41, while cash outflow was 568,649.24, resulting in a net cash flow of 12,020,770.17, compared to -1,620,487.88 previously[56] - The company reported a significant decrease in cash and cash equivalents, with a net decrease of 2,604,906.49 compared to -51,893,336.39 last year[56] Assets and Liabilities - Total assets increased by 3.66% to CNY 474,853,107.79 as of March 31, 2024, compared to CNY 458,091,452.82 at the end of 2023[12] - Total liabilities increased to CNY 195,129,520.70 from CNY 174,968,345.64, reflecting a rise of approximately 11.5%[45] - Current assets increased to CNY 290,555,082.54 as of March 31, 2024, up from CNY 273,910,270.25 on December 31, 2023, representing a growth of approximately 6.4%[43] - The company's total assets reached CNY 474,853,107.79, up from CNY 458,091,452.82, indicating a growth of about 3.5%[45] Shareholder Information - The total number of ordinary shares was 68.5 million, with 37.80% being unrestricted shares and 62.20% being restricted shares[19] - Major shareholders include Bi Chunguang with 26.72% and Bianjing with 19.85% of the shares[20] - There were no pledged or judicially frozen shares among the major shareholders[22] Research and Development - Research and development expenses increased by 46.57% to CNY 1,999,529.25, reflecting the company's commitment to enhancing R&D efforts[14] - Research and development expenses for Q1 2024 were CNY 1,999,529.25, compared to CNY 1,364,229.54 in Q1 2023, representing an increase of approximately 46.5%[49] Debt and Financing - The company's debt-to-asset ratio rose to 41.09% from 38.20% year-over-year, indicating increased leverage[12] - Short-term borrowings rose by 44.38% to CNY 40,955,897.22, driven by the need for working capital[14] - The company maintained its long-term borrowings at CNY 26,400,000.00, unchanged from the previous year[48] Other Financial Metrics - The weighted average return on equity dropped to -1.19% from 7.61% in the previous year, indicating a decline in profitability[12] - The company reported a credit impairment loss of CNY -417,522.35 in Q1 2024, worsening from CNY -333,763.53 in Q1 2023[50] - Total operating costs for Q1 2024 amounted to CNY 17,378,642.04, compared to CNY 42,403,116.82 in Q1 2023, indicating a decrease of about 58.9%[49]

证券代码：838810 证券简称：春光药装 公告编号：2024-015 辽宁春光制药装备股份有限公司 2023 年年度独立董事述职报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 我作为辽宁春光制药装备股份有限公司（以下简称"公司"）的独立董事，2023 年度，严格按照《公司法》《证券法》《北京证券交易所股票上市规则（试行）》 《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等有关法律、法 规及《公司章程》《独立董事工作制度》的规定和要求，本着对全体股东负责的 态度，认真履行独立董事职责和义务，谨慎、认真、勤勉地行使公司所赋予的各 项权利，充分发挥独立董事作用。对公司重大事项发表客观、审慎、公正的事前 认可或独立意见，积极维护公司整体利益和全体股东特别是中小股东的合法权益。 现将 2023 年度履行独立董事职责的工作情况汇报如下： 一、独立董事的基本情况 房华先生，1978 年 7 月出生，中国国籍，无境外永久居留权，法学学士。 2000 年 10 月至 2004 年 5 月，任辽宁省律 ...

证券代码：838810 证券简称：春光药装 公告编号：2024-020 辽宁春光制药装备股份有限公司 2023 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、权益分派预案情况 根据公司 2024 年 4 月 25 日披露的 2023 年年度报告（财务报告已经审计）， 截至 2023 年 12 月 31 日，上市公司合并报表归属于母公司的未分配利润为 63,772,960.72 元，母公司未分配利润为 65,119,995.20 元。 公司本次权益分派预案如下：公司目前总股本为 68,500,000 股，以未分配利 润向全体股东每 10 股派发现金红利 1.00 元（含税）。本次权益分派共预计派发 现金红利 6,850,000.00 元。 公司将以权益分派实施时股权登记日应分配股数为基数，如股权登记日应分 配股数与目前预计不一致的，公司将维持分派比例不变，并相应调整分派总额。 实际分派结果以中国证券登记结算有限责任公司北京分公司核算的结果为准。 二、审议及表决情况 （一）董事 ...

辽宁春光制药装备股份有限公司 审计报告 大华审字[2024]0011005603 号 大华会计师事务所(特殊普通合伙) Da Hua Certified Public Accountants (Special General Partnership) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.gn 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn） 报告编码:京24KG 辽宁春光制药装备股份有限公司 审计报告及财务报表 (2023年1月1日至 2023年12月31日止) | | 录 | 页 次 | | --- | --- | --- | | 审计报告 | | 1-7 | | 已审财务报表 | | | | 合并资产负债表 | | 1-2 | | 合并利润表 | | 3 | | 合并现金流量表 | | 4 | | 合并股东权益变动表 | | 5-6 | | 母公司资产负债表 | | 7-8 | | 母公司利润表 | | 9 | | 母公司现金流量表 | | 10 | | 母公司股东权益变动表 | | 11-1 ...

Financial Forecast Revision - The company revised its 2023 net profit forecast to approximately CNY 14,485,200, a decrease of 64.68% compared to the previous year's CNY 41,013,200[4] - The revision was due to increased provisions for expected credit losses on accounts receivable and contract assets, as well as adjustments to prepaid accounts over three years[5] - The performance period for the forecast is from January 1, 2023, to December 31, 2023[3] Risk Warning and Disclosure - The company has issued a risk warning regarding the financial data, advising investors to refer to the detailed annual report for accurate figures[8] - The board of directors has apologized for any inconvenience caused by the forecast revision and committed to improving information disclosure quality in the future[7]

Corporate Recognition and Achievements - In 2023, the company was awarded the title of "Integrity Enterprise" by Jinzhou Credit Association and Jinzhou Small and Medium Enterprises Federation[4] - The company participated in the 25th Annual Golden Bull Award Ceremony in November 2023, winning the "Golden Bull Small Giant Award"[4] - The company was recognized as one of the first "Explosive Products" enterprises in Jinzhou in May 2023[6] Subsidiaries and Business Structure - The company established a wholly-owned subsidiary, Liaoning Jinwang Equipment Installation Engineering Service Co., Ltd., in September 2023[4] - The company included three subsidiaries in the consolidated financial statements, with two newly established subsidiaries in 2023, holding 100% and 60% stakes respectively[114] Financial Performance - The company's operating revenue for 2023 was ¥165,071,927.79, a decrease of 23.61% compared to ¥216,082,516.98 in 2022[27] - The net profit attributable to shareholders for 2023 was ¥14,485,196.39, down 64.68% from ¥41,013,230.25 in 2022[27] - The gross profit margin for 2023 was 32.25%, significantly lower than 47.13% in 2022[27] - Total assets increased by 5.55% to ¥458,091,452.82 at the end of 2023, compared to ¥433,992,572.72 at the end of 2022[29] - Total liabilities rose by 15.08% to ¥174,968,345.64 at the end of 2023, up from ¥152,040,697.45 at the end of 2022[29] - The company's cash flow from operating activities decreased by 83.27% to ¥8,083,726.75 in 2023, compared to ¥48,321,113.32 in 2022[29] - The weighted average return on equity (ROE) based on net profit attributable to shareholders was 5.13% in 2023, down from 34.87% in 2022[27] - The basic earnings per share for 2023 was ¥0.21, a decline of 72.93% from ¥0.78 in 2022[27] Research and Development - The company holds a total of 41 authorized patents, including 12 invention patents, reflecting strong technological innovation capabilities[38] - The company has established a research and innovation mechanism focusing on customer and market needs, enhancing its R&D capabilities through partnerships with universities and research institutions[38] - The company is actively pursuing new technologies and product development, although specific new products were not detailed in the report[88] - R&D expenditure for the current period amounted to ¥9,209,998.60, representing an increase of 3.37% compared to the previous period's ¥8,909,482.96[94] - The increase in R&D costs was driven by a 76.71% rise in material costs due to a shift from collaborative to independent R&D projects[95] Market and Industry Trends - The packaging equipment industry is experiencing growth driven by digital transformation and smart manufacturing, increasing demand for intelligent equipment and production lines[49] - The global packaging industry market size grew from $843.8 billion in 2015 to $914.7 billion in 2019, then decreased to $859.9 billion in 2020 due to economic downturn, with an expected growth to $1.13 trillion by 2030[50] - The global packaging equipment market was valued at $43.6 billion in 2020 and is projected to reach $54.9 billion by 2027, with a CAGR of 3.3%[50] Client Relationships and Sales - Major clients accounted for 39.96% of total sales, with the largest client, Yili, contributing CNY 27,316,911.57, representing 16.55% of total sales[76] - The company has established stable partnerships with leading firms in the pharmaceutical and food sectors, enhancing its market reputation and brand influence[54] Financial Management and Investments - The company has secured loans from various banks, including a 160,000,000.00 CNY loan from Dian Guan Ke Construction Bank, with a repayment period extending to 2031[151] - The company has ongoing investments in the intelligent automation equipment production base, with total actual investment reaching CNY 121,208,930.37 by the end of the reporting period[83] - The company reported a total of 428,400.00 yuan in litigation as a defendant, representing 0.15% of the total net assets at the end of the reporting period[132] Governance and Compliance - The company has established new corporate governance systems during the year, enhancing its internal control mechanisms[194] - The governance mechanism effectively protects the rights of all shareholders, ensuring equal rights and participation in decision-making processes[197] - Major decisions such as external guarantees, investments, and related transactions were conducted in accordance with internal control procedures and legal regulations[200] Employee Management and Development - The company has implemented a competitive salary policy and provides various employee benefits, including health check-ups and commercial insurance[188] - The number of management personnel increased from 23 to 39, with a net addition of 16 personnel during the reporting period[186] - The company has a stable core technical team, with R&D capabilities that are improving, ensuring that their packaging equipment meets or exceeds the functionality of similar imported equipment[125]

辽宁春光制药装备股份有限公司 募集资金存放与使用情况鉴证报告 大华核字|2024]001101118 号 大华会计师事务所(特殊普通合伙) Da Hua Certified Public Accountants (Special General Partnership) 您可使用手机"扫一扫"或进入"注册会计师行业练一些管理会（L 辽宁春光制药装备股份有限公司 募集资金存放与使用情况鉴证报告 (2023 年度) 目 页 次 r 募集资金存放与使用情况鉴证报告 1-2 if 辽宁春光制药装备股份有限公司 2023 年度募 1-6 集资金存放与实际使用情况的专项报告 北京市海淀区西四环中路 16 号院 7 号楼 12 层 电话:86(10) 5835 0011 传真:86(10) 583 募 集 资 金 存 放 与 使 用 情 况 鉴 证 报 告 一、董事会的责任 辽宁春光公司董事会的责任是按照中国证券监督管理委员会《上 市公司监管指引第2号 -- 上市公司募集资金管理和使用的监管要 求(2022年修订)》、北京证券交易所发布的《北京证券交易所股 票上市规则(试行)》以及《北京证券交易所上市公司持续监管临时 公告 ...

辽宁春光制药装备股份有限公司 董事会关于独立董事独立性自查情况的专项报告 证券代码：838810 证券简称：春光药装 公告编号：2024-022 （五）独立董事不是公司及公司控股股东、实际控制人或者其各自的附属企 业有重大业务往来的人员，未在有重大业务往来的单位及其控股股东、实际控制 人处任职； （六）独立董事不是为公司及公司控股股东、实际控制人或者其各自附属企 业提供财务、法律、咨询、保荐等服务的人员，包括但不限于提供服务的中介机 构的项目组全体人员、各级复核人员、在报告上签字的人员、合伙人、董事、高 级管理人员及主要负责人； （七）独立董事最近十二个月内未曾具有第一项至第六项所列举情形； （八）独立董事不是法律、行政法规、中国证监会规定、证券交易所业务规 则和公司章程规定的不具备独立性的其他人员。 综上，董事会认为公司在任独立董事具备任职条件，不存在影响其独立性的 情形。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 根据中国证券监督管理委员会《上市公司独立董事管理办法》及北京证券交 易所《北京证 ...

证券代码：838810 证券简称：春光药装 公告编号：2024-017 辽宁春光制药装备股份有限公司 2023 年年度独立董事述职报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 我作为辽宁春光制药装备股份有限公司（以下简称"公司"）的独立董事，2023 年度，严格按照《公司法》《证券法》《北京证券交易所股票上市规则（试行）》 《北京证券交易所上市公司持续监管指引第 1 号——独立董事》等有关法律、法 规及《公司章程》《独立董事工作制度》的规定和要求，本着对全体股东负责的 态度，认真履行独立董事职责和义务，谨慎、认真、勤勉地行使公司所赋予的各 项权利，充分发挥独立董事作用。对公司重大事项发表客观、审慎、公正的事前 认可或独立意见，积极维护公司整体利益和全体股东特别是中小股东的合法权益。 现将 2023 年度履行独立董事职责的工作情况汇报如下： 一、独立董事的基本情况 张丽女士，1977 年 9 月出生，中国国籍，无境外永久居留权，大专学历， 中国注册会计师。2000 年 7 月至 2008 年 9 ...